Conference Program Day 1
Monday, 25th March
| 11.00 | Registration | |
| 11.30 | Anatomy of Melancholy – revision of neuroanatomy relevant to depression Speaker: Laith Alexander (Kings College London) |
|
| 12.00 | Lunch – Early Career Researchers Lunch (location TBC) | |
| 12.45 | Welcome and Introduction Speaker: Rupert McShane (University of Oxford, UK) |
|
| 12.55 | Lateral habenula and social dominance Speaker: Hailan Hu (Zhejiang University, China) |
|
| 13.55 | Implementation of emerging psychedelics: models of support and interventional psychiatry Speaker: Steve Levine (COMPASS Pharmaceuticals, USA) |
|
| 14.25 | RCT of ketamine for OCD Speaker: Peter van Roessel (Stanford University, USA) |
|
| 15.00 | Tea | |
| 15.30 | Addiction potential of ketamine enantiomers and metabolites, and of esmethadone Speaker: Mike Michaelides (National Institute on Drug Abuse, USA)
|
|
| 16.00 | Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine (the GO-MARK study) Speaker: Luke Jelen (King’s College London, UK)
|
|
| 16.30 | Opioid use diminishes placebo antidepressant response independently of pain in a ketamine depression trial Speaker: Theresa Lii (Stanford University, USA) |
|
| 18.00 | Debate at Holywell Music room followed by reception at the Weston Library This house believes that oral home treatment with ketamine could be widely and safely used for the treatment of resistant depression |
|
| Speakers For: | Rupert McShane (University of Oxford, UK) TBC, Robert Schoevers (Groningen University, The Netherland) TBC |
|
| Speakers Against: | Alan Schatzberg (Stanford University, USA), Zoe Cormier (Author and Journalist, UK) |
|
| Chair: | TBC | |
Conference Program Day 2
Tuesday, 26h March – morning
| 09.00 | Pilot RCT of ketamine + Written Exposure Therapy for PTSD Speaker: Adriana Feder (Icahn School of Medicine at Mount Sinai, USA) |
| 09.30 | Comorbid PTSD and childhood trauma: impact on ketamine’s efficacy in TRD Speaker: Danica Johnson (University of Toronto, Canada) |
| 10.00 | Prucalopride (5HT4a agonist) plus ketamine: additive effects on stress Speaker: Christine Denny (Columbia University, USA) |
| 10.30 | Coffee Break |
| 11.00 | Opioid-dependent mechanisms of ketamine antidepressant action Speaker: Alan Schatzberg (Stanford University, USA) |
| 11.40 | EEG gamma oscillations as a prognostic marker for IV ketamine in TRD Speaker: Sanjay Mathew (Baylor College of Medicine, USA) |
| 12.10 | Targeted ketamine delivery to the thalamus using ultrasound Speaker: Raag Airan (Stanford University, USA)
|
| 12.30 | Lunch |
Conference Program Day 2
Tuesday, 26h March – afternoon
| 13.15 | Ketamine vs. ECT: implications for clinical practice, policy and future research Speaker: Amit Anand (Harvard Medical School, USA)
|
| 13.45 | Machine learning to predict response to ECT vs (es)ketamine Speaker: Michael Henry (Harvard Medical School, USA) |
| 14.15 | RCT of ketamine for depression in Parkinson’s disease Speaker: Sophie Holmes (Yale University) |
| 14.35 | Short talk sessions IV ketamine: RWE following induction- Speaker: Patrick Oliver (MindPeace Clinics, USA) IV esketamine in TRD – RWE following induction – Speaker: Tiago Gill (Centro de Cetamina, Brazil) Predictors of ketamine response in 1047 patients: machine learning and RWE – Speaker: George Wohlfold (University of Virginia, USA) |
| 15.15 | Tea |
| 15.45 | Title TBC Speaker: Robert Schoevers (University of Groningen, The Netherlands) |
| 16.15 | Mesmer, ketamine and cardiac surgery: mechanisms of non-specific effects Speaker: Gerard Sanacora (Yale Universiy, USA) |
| 18.45 | Pre-dinner drinks – Fellows Garden, Exeter college |
| 19.30 | Conference Dinner – Exeter College Dining Hall |
Conference Program Day 3
Wednesday, 27h March – morning
| 09.00 | Mouse model of anorexia: effects of ketamine in adults and adolescents Speaker: Chiye Aoki (New York University, USA) |
| 09.30 | RCT of dextromethorphan vs psilocybin: effects in healthy volunteers with history of hallucinogen use Speaker: David Mathai (Johns Hopkins, USA) |
| 10.00 | Psilocybin and ketamine: two side of the same coin? Speaker: David Nutt (Imperial College London, UK) |
| 10.30 | Coffee Break |
| 11.00 | R-Ketamine for Treatment Resistant Depression Speaker: David Feifel (University of California, USA) |
| 11.30 | Title TBC Speaker: Celia Morgan (University of Exeter, UK) |
| 12.00 | Bladder symptoms: prospective long-term data in 295 patients Speaker: Rupert McShane (University of Oxford, UK) |
| 12.30 | Lunch
|
Conference Program Day 2
Wednesday, 27h March – afternoon
| 13.15 | Dose finding study of prolonged release oral ketamine formulation Speaker: Hans Eriksson (Ketabon, USA)
|
| 13.45 | Keticap immediate release, abuse deterrent: Phase 1 data Speakers: Mario Juruena (Kings College, UK) |
| 14.15 | Pilot RCT of ethosuximide in TRD: efficacy and safety Speakers: Shaohua Hu (Zhejiang University, China) |
| 14.35 | Short talk sessions IV ketamine: RWE following induction- Speaker: Patrick Oliver (MindPeace Clinics, USA) EEG dissociation – Speaker: Marco Fabus (University of Oxford, UK) Influence of ketamine on the effect of expectations on perceptual and emotional learning – Speaker: Lilian Weber (University of Oxford, UK) Talk TBC – Speaker: TBC |
| 15.15 | Tea |
| 15.45 | Leveraging the diverse properties of ketamine to address psychiatric challenges Speaker: Elias Dawkar (Columbia University, USA) |
| 16.15 | Long-term safety and durable efficacy of esketamine in TRD and ESCAPE-TRD Speaker: Wayne Drevets (Janssen Pharmaceutical, USA) |
| 16.45 | Closing remarks Speaker: Rupert McShane, University of Oxford, UK |